ArticlePDF Available

Following “the Roots” of Kratom ( Mitragyna speciosa ): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries


Abstract and Figures

The use of substances to enhance human abilities is a constant and cross-cultural feature in the evolution of humanity. Although much has changed over time, the availability on the Internet, often supported by misleading marketing strategies, has made their use even more likely and risky. This paper will explore the case of Mitragyna speciosa Korth. (kratom), a tropical tree used traditionally to combat fatigue and improve work productivity among farm populations in Southeast Asia, which has recently become popular as novel psychoactive substance in Western countries. Specifically, it (i) reviews the state of the art on kratom pharmacology and identification; (ii) provides a comprehensive overview of kratom use cross-culturally; (iii) explores the subjective experiences of users; (iv) identifies potential risks and side-effects related to its consumption. Finally, it concludes that the use of kratom is not negligible, especially for self-medication, and more clinical, pharmacological, and socioanthropological studies as well as a better international collaboration are needed to tackle this marginally explored phenomenon.
This content is subject to copyright. Terms and conditions apply.
Research Article
Following (the Roots)of Kratom (Mitragyna speciosa):
The Evolution of an Enhancer from a Traditional Use to Increase
Work and Productivity in Southeast Asia to a Recreational
Psychoactive Drug in Western Countries
Eduardo Cinosi,1,2 Giovanni Martinotti,1,2 Pierluigi Simonato,1
Darshan Singh,3Zsolt Demetrovics,4Andres Roman-Urrestarazu,5,6
Francesco Saverio Bersani,1,7 Balasingam Vicknasingam,3Giulia Piazzon,1
Jih-Heng Li,8Wen-Jing Yu,8Máté Kapitány-Fövény,4,9,10 Judit Farkas,4,10
Massimo Di Giannantonio,2and Ornella Corazza1,7
Hateld, Her ts AL10 9AB, UK
2Department of Neuroscience, Imaging and Clinical Sciences, Gabriele D’Annunzio University, Chieti, Italy
3Centre for Drug Research, Universiti Sains, Penang, Malaysia
4Institute of Psycholog y, E¨
os Lor´
5London School of Economics and Political Science, LSE Health and Social Care, London, UK
6Department of Psychiatry, University of Cambridge, Cambridge, UK
7Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
8School of Pharmacy and Ph.D. Program in Toxicology, Kaohsiung Medical University, Kaohsiung, Taiwan
9Faculty of Health Sciences, Semmelweis University, Budapest, Hungary
o Gyula Hospital, National Institute of Psychiatry and Addictions, Budapest, Hungary
Correspondence should be addressed to Ornella Corazza;
Received  August ; Revised  October ; Accepted  October 
Academic Editor: Yu-Ping Tang
Copyright ©  Eduardo Cinosi et al. is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
e use of substances to enhance human abilities is a constant and cross-cultural feature in the evolution of humanity. Although
much has changed over time, the availability on the Internet, oen supported by misleading marketing strategies, has made their use
even more likely and risky. is paper will explore the case of Mitragyna speciosa Korth. (kratom), a tropical tree used traditionally
to combat fatigue and improve work productivity among farm populations in Southeast Asia, which has recently become popular
as novel psychoactive substance in Western countries. Specically, it (i) reviews the state of the art on kratom pharmacology and
identication; (ii) provides a comprehensive overview of kratom use cross-culturally; (iii) explores the subjective experiences of
users; (iv) identies potential risks and side-eects related to its consumption. Finally, it concludes that the use of kratom is not
negligible, especially for self-medication, and more clinical, pharmacological, and socioanthropological studies as well as a better
international collaboration are needed to tackle this marginally explored phenomenon.
1. Introduction
Kratom (Mitragyna speciosa Korth., of the Rubiaceae family)
is a –-metre high tropical tree, indigenous to Southeast
Asia, the Philippines, and New Guinea. Traditionally, in
certain regions of Southeast Asia, the chopped fresh or dried
leaves of the tree are chewed or made into tea by local manual
labourers to combat fatigue and improve work productivity
[]. In addition, kratom preparations have also been used
for centuries during socioreligious ceremonies and to treat
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 968786, 11 pages
BioMed Research International
1% 2%
Mitragynine (C23H30 N2O4)
Paynantheine (C23H28N2O4)
Hydroxymitragynine (C23H30N2O5)
Speciogynine (C23H30 N2O4)
Speciociliatine (C23H30N2O4)
F : An estimate of ai kratom extract composition. e
phytochemicals isolated from various parts of the tree include
overall  structurally related alkaloids as well as several avonoids,
terpenoid saponins, polyphenols, and various glycosides.
various medical conditions, such as morphine dependence
in ailand [], and as opium substitute in Malaya []. It
has been suggested that the genus was given the “Mitragyna
name by the Dutch botanist Korthals because the leaves and
the stigmas of the owers of the plant resemble the shape
of a bishop’s mitre []. However, considering its variety of
uses, it could be speculated that the term derives from the
“Mithraic cults,” seen as a source of spiritual transcendence
for thousands of years [].
Kratom preparations contain varying amounts of several
phytochemicals, making their pharmacological and toxi-
cological evaluation unique and dicult (Figure ). e
main psychoactive components in the leaves are alkaloids
mitragynine and -hydroxymitragynine both found only in
Mitragyna speciosa, but other analogues have been identied
(e.g., speciogynine, paynantheine, and speciociliatine) [,
] (Figure ). e eects of kratom in humans are dose-
dependent where small doses produce stimulatory eects
amphetamines, while larger dosages tend to be associated
with sedative-narcotic eects that resemble drugs such as
opiates [].
Imported to Western countries from Southeast Asia,
kratom has become in recent years a popular enhancer,
which could also be classied as novel psychoactive substance
(NPS) []. Beyond kratom, some of the most widely used
psychoactive plants, largely not under international control,
include Salvia divinorum,khat(Catha edulis), Hawaiian baby
woodrose seeds (Argyreia nervosa), y agaric (Amanita mus-
caria), “Magic Mushrooms” (Psilocybe and related species),
Peyote (Lophophora williamsii), Ayahuasca (Banisteriopsis
caapi and Psychotria viridis), and “Genie” (a smoking mixture
containing multiple plant materials and of dubious phar-
macognostical identity) []. Natural products oen used
as enhancers are exceptionally complex in terms of their
chemistry. is adds complexity of their pharmacological
eects, with a paucity of data relating to the toxicology of
these materials, and even less regarding their interactions
with conventional drugs of abuse []. is is further compli-
cated by the possibility of adulteration processes []. e level
of complexity, variability, and the unknown nature of these
choactive materials, could oer further risks of ill health by
misadventure, with potentially life-threatening consequences
[]. In this scenario, predictions of novel psychoactive drug
trends in Western countries specically suggest that kratom
e aim of the present study was to study this new
phenomenon by (i) reviewing the state of the art on kratom
pharmacology and identication; (ii) providing a compre-
hensive overview of kratom use cross-culturally, ranging
from its traditional use in native societies in Southeast Asia to
its more recent diusion as a NPS in Western countries; (iii)
exploring the subjective experience of users; (iv) identifying
risks and side-eects related to its consumption.
2. Materials and Methods
A collaborative and multidisciplinary eort to study the
rapid diusion of kratom was carried internationally by ten
research centres: the School of Life and Medical Sciences,
University of Hertfordshire (United Kingdom), Department
of Neuroscience, Imaging and Clinical Sciences, Gabriele
D’Annunzio University, Chieti (Italy), Centre for Drug
Research, Universiti Sains, Penang (Malaysia), Institute of
Psychology, E¨
os Lor´
and University, Budapest (Hungary),
London School of Economics and Political Science, LSE
Health and Social Care, London (United Kingdom), Depart-
ment of Psychiatry, University of Cambridge, Cambridge
(United Kingdom), Department of Neurology and Psychi-
atry, Sapienza University of Rome, Rome (Italy), School
of Pharmacy and Ph.D. Program in Toxicology, Kaohsiung
Medical University, Kaohsiung (Taiwan), Faculty of Health
Sciences, Semmelweis University, Budapest (Hungary), and
o Gyula Hospital National Institute of Psychiatry and
Addictions, Budapest (Hungary). A review of the literature
formed in three databases: PsycINFO, PubMed, and Med-
scape. Keywords used to carry out the database searches
included the following: “kratom”, “Mitragyna speciosa”,
“mitragynine”, and “-hydroxymitragynine”. Peer-review
data that emerged from the search were integrated with
an exploratory qualitative assessment of  websites, drug
fora, and other online resources (i.e., e-newsgroups, chat-
rooms, mailing lists, e-newsletters, and bulletin boards). is
was carried out on a regular weekly basis (between January
three languages (English, Italian, and Hungarian). Once the
substance availability of information was identied, further
specic searches were carried out for narratives focusing on
the following issues: (i) motivations behind its recreational
use and possible trends of misuse; (ii) the nature of its
eects on users, including adverse reactions and polydrug
misuse/idiosyncratic combinations; (iii) any other relevant
BioMed Research International
information. For the purpose of reporting the results in this
paper, any data collected from online fora, such as usernames
and complete URLs for specic threads that were considered
personal identiable, were anonymized. Additional searches
were conducted using the Global Public Health Intelligence
Network (GPHIN), a secure Internet-based early warning
system developed by Health Canada and the World Health
Organization (WHO), which monitors media reports in six
languages, Arabic, Chinese, English, French, Russian, and
Permission for the study was granted by the School of
Pharmacy Ethics Committee, University of Hertfordshire,
Hateld, United Kingdom (November ; PHAEC/-).
3. Results
 studies emerged from the literature review and were
critically analysed. Among these,  results were considered
not relevant (resulting duplicated, botanical studies, or stud-
ies focusing mainly on other selected chemical compounds)
and therefore excluded. e remaining  articles were
further qualitatively analysed and thematically divided in
three main areas of interest related to Mitragyna speciosa
and its main constituents: () in vitro and preclinical data
on pharmacology and behavioral eects (𝑁=51), ()
laboratoristic techniques for identication/characterization
(𝑁=26), and () epidemiological/toxicological reports on
humans (𝑁=18). Data on kratom that emerged from the
online searches were identied, monitored, and registered
into  categories: (1) epidemiology and motivation of use; (2)
legal status, methods of purchase, and typical price; (3) forms
of kratom use; (4) subjective pleasurable eects, adverse
eects, and fatal intoxications related to kratom; (5)pattern of
polyabuse. e results from the review of scientic literature
and online sources were comprehensively integrated and
summarized in the following three main subsections: (i)
preclinical data about pharmacology and identication of
kratom constituents; (ii) kratom use in humans in Southeast
Asia; (iii) kratom use in humans in Western countries.
3.1. Pharmacology and Identication of Kratom Constituents.
Kratom has both opioid- and psychostimulant-like subjective
eects []. e phytochemicals isolated from various parts
alkaloids [] of which mitragynine (Figure ) is the most
important with up to % purity in the extract of leaves
from ailand, and only % in kratom leaves from Malaysia.
is alkaloid is the one responsible for analgesic activity
opioid agonist property []. Although mitragynine can act
on the mu (𝜇), kappa (𝜅), and delta (𝛿) opioid receptors, it
is structurally dierent from morphine and other compo-
nents from the opioid family; the reason why it has been
suggested is that it might also present with a more broad
in kratom (including speciogynine (%), paynantheine (%),
and speciociliatine (%) (Figure )) are indole alkaloids of the
Corynanthe-type, possessing a monoterpene (iridoid) moiety
[]. Dierently, -hydroxymitragynine (Figure ), a minor
constituent (%) of M. speciosa, when isolated demonstrates
a potent antinociceptive activity in mice []. It is now
considered to be a major contributory factor for the analgesic
properties of M. speciosa due to its selectivity for 𝜇-and
𝜅-opioid receptors []. e presence of a hydroxyl group
at C- increases the potency of -hydroxymitragynine to
be - and -fold higher than morphine and mitragynine,
respectively, both in vitro and in vivo [, , ]. is might
be one of the main pharmacological markers of kratom
products’ quality and potency. Recent studies further revealed
how complex is kratom’s pharmacology, involving a 𝜅-opioid
and dopamine D receptors interaction in its various eects
[]. Serotonergic and adrenergic pathways have also been
involved in the eects of mitragynine, mostly due to its broad
anity to dierent receptors []. Indeed, the pharmacologi-
cal mechanisms responsible for stimulant activity are yet to be
clearly established []. Another confounding factor might be
the action of some other isolated compounds(speciociliatine,
speciogynine, and paynantheine), for example, whose eects
were not inhibited by naloxone in animal studies [, ].
It is possible that mitragynine is relatively safe at lower
subchronic dose but exhibits toxicity at a highest dose
[]. However, the erratic pharmacology of kratom makes
it dicult to dene a specic dose threshold. According to
online reports and traditional experiences, subjective eects
of kratom depend on the dosage: at low to moderate dose
(–g) it has a mild pleasant stimulant eect; at moderate-
high dose (– g) the compound has opioid-like analgesia
and sedation [, ]. No studies have been conducted so
far to determine the blood concentration in patients, and
future approach should consider this point in order to prevent
overdose, considering the possible risk of no response to
naloxone [, ]. e standard half-life of mitragynine is
. ±∼ hr, depending upon the individuals natural levels
of enzymes and other factors [, ]. -Hydroxymitragynine
has quite a bit shorter duration, with an average half-life of
. ±. hours [, ]. Recent evidences suggest that the
hydrophobicity, poor water solubility, high variability of drug
release in simulated biological uids, and acid degradable
characteristics of mitragynine probably further inuence the
large variability of its pharmacological responses reported
and brain histopathological changes, as well as hematological
and biochemical changes in mice []. Mitragynine, -
hydroxymitragynine, and mitraphylline exhibit high plasma
protein binding (>%) determined by equilibrium dialysis
clinical eects on CYPA activity, on the other hand
mitragynine might inhibit other cytochrome P enzyme
activities, specically CYPD [, ]. ese data indicate
the possibility of a drug interaction if mitragynine and -
hydroxymitragynine are coadministered with drugs that are
P-glycoprotein substrates [].
Current preclinical information on kratom suggests that
this ethnodrug, containing several dierent active alkaloids,
has a harmful toxicological prole and must be studied in
detail in order to better dene its potential as therapeutic
drug []. Acute administration of mitragynine produces
BioMed Research International
anxiolytic-like eects attributed to the interactions among
opioidergic receptor systems []. Other authors attempted
to reveal a possible link with the stress-related corticotropin
pathway []. Other evidences show that mitragynine exerts
an antidepressant eect in animal behavioral model inter-
acting with neuroendocrine HPA axis systems []. Among
its potential benets, in addition to analgesic activity [,
], mitragynine seems to be also a key component for
the anti-inammatory properties of kratom by suppressing
prostaglandin E (PGE-) production in the cyclooxygenase
 (COX-) pathway []. Moreover, some authors claim
that kratom might be promising antioxidant and anticancer
or chemopreventive compounds []. Kratom extracts and
mitragynine have been shown to possess cytotoxicity to some
human cancer cell lines, namely, SH-SYY cells (neuronal
cells), [] and avoid the tolerance and dependence on
chronic morphine treatment in mice as well as in human
neuroblastoma SK-N-SH cell [, ]. Other interesting prop-
erties of the compound might be the capability to modulate
muscle neurogenic contraction [–] and gastric secretion
developed as new therapeutic agents, there are also possible
serious adverse eects of these materials under investigation.
ere have been dierent studies showing serious conditions
aer repeated administration as elevated blood pressure,
nephrotoxic eects [], impaired cognition and behaviour
[, ], dependence potential [], and hepatic failure [,
]. e onset of liver injury is described to occur within
 to  weeks of starting regular use of kratom powder or
tablets, with symptoms of fatigue, nausea, pruritus, and dark
seems to be typically cholestatic and can be severe with
serum bilirubin levels rising above  mg/dL []. Kratom
constituents were also identied to be potentially cardiotoxic,
ideally potentiating Torsade de Pointes through inhibition
of rapid delayed rectier potassium current (IKr) in human
cardiomyocytes [].
At present, kratom constituents are not detected by
conventional drug screening tests: advanced tests like liq-
uid chromatography-tandem or ion-mass spectrometry are
required [].
3.2. Kratom Use in Southeast Asia
3.2.1. Diusion and Modalities of Consumption. Mitragyna
speciosa (Rubiaceae) is an indigenous plant of Southeast Asia.
or “biak” (Malaysia), or as “krathom” (ailand, “thom”
in Southern ailand) and has been used for millennia (a)
as a stimulant; (b) as a remedy in traditional medicine;
and (c) in social context [, ]. Historically, manual
labourers (e.g., sherman, farmers, and rubber-tappers) in
northern Malaysia and southern ailand commonly used
ketum leaves to improve their work productivity under the
sweltering sun and to relieve fatigue []. Rural folk have
traditionally ingested ketum leaves to self-treat common
medical problems (e.g., diabetes, diarrhoea, fever, and pain)
as an opium substitute in Malaya during opium scarcity [].
It is still popularly consumed in Asian communities during
social gatherings in the village [].
Traditionally, the fresh or dried leaves of kratom are
chewed or brewed into tea or smoked []. Ketum is bitter
and sugar or sweet beverages are commonly added to mask
its taste []. To experience vigour and euphoria, traditional
“kratom eaters” chew one to three fresh leaves at a time
[, ]. Regular and addicted users chew – times a day [].
about . g and a dry leaf about . g and twenty kratom
leaves contain about mg of mitragynine; no information
is available on other active compounds of the plant. Ketum
is currently widely available in many Asian countries (e.g., in
Malaysia) where it can be easily bought from ketum traders
in the community []. Consumers can be classied into two
improve physical tolerance to laborious work and the second
polydrug users who attempt to manage drug withdrawal
symptoms or reduce the intake of other opiates like heroin
[]. A recent study showed that out-of-treatment opiate users
in Malaysia oen use ketum to reduce their dependence
on illicit opiate as well as to ameliorate opiate withdrawal
symptoms [].
At present, there is no systematic data on the prevalence
of ketum use in all the native countries, but it seems to
be considerable in Malaysia and ailand. A survey per-
formed in  investigating kratom use in ailand (,
respondents aged – years) indicated that the lifetime,
past year, and past  days prevalences for kratom were
.%, .%, and .%, respectively []. ese gures, with
the exception of lifetime use, were signicantly higher than
those for cannabis making kratom the most widely used illicit
drug in ailand. Again in ailand past -day prevalence
studies among –-year-old students (𝑛 = 8 70812148)
in , , and  showed an increase in the lifetime
use of kratom (from .% to .%) []. Another study
in ailand in  showed a prevalence of psychoactive
drugs in , motor vehicle drivers: .% were positive to
mitragynine []. Overall, reported seizures linked to kratom
quintupled in ailand from  to , far higher than
those reported for any other drug []. Kratom reported
seizures in Malaysia and Myanmar also reached record levels
in , at roughly one ton each []. Conversely, in Taiwan,
heroin, methamphetamine, and some new drugs such as syn-
thetic cathinones (methylone, mephedrone, and MDPV) and
synthetic cannabinoids (K) have been identied since s
according to the Substance Abuse Monitoring and Reporting
Systems (SAMRS), which is a national data collection system
for substance abuse []. However, use of kratom and its
major alkaloid mitragynine has not been detected via the
collected information from the SAMRS []. erefore, it
could be suggested that kratom may not yet be a drug of
choice in Taiwan and might still be considered a rather
culture-bounded phenomenon in Asian countries.
e possession of kratom leaves has been illegal in
ailand since  []. Kratom is also controlled in a few
other countries in the region (Malaysia and Myanmar) and
elsewhere (Australia, Bhutan) []. In parallel, kratom-related
BioMed Research International
arrests more than doubled between  and  in both
Myanmar and ailand []. To control its widespread abuse,
ketum was banned in Malaysia and regulated under the
Poisons Act  []. ose caught for possessing or pro-
cessing ketum leaves can be ned for approximately RM
, (US ) or imprisoned if found guilty []. e
Malaysian government is in the midst of regulating ketum
under the Dangerous Drugs Act , which will consider the
substances as harmful as opiates and amphetamines [].
3.2.2. Stigma and Side-Eects. Among rural folk, the believe
that kratom is a better alternative to illicit drugs, such
as heroin and methamphetamine, is still diuse and it is
mainly used for its invigorating-like eects [, ]. Five
to ten minutes aer kratom consumption users describe
themselves as feeling happy, strong, and active, especially
among those working in the agricultural sector []. ey
claim that “their mind is calm” aer the consumption of
the drug []. Overall, there is no real social stigma towards
ketum users and being dependent on ketum is not seen as
a major problem or taboo in Malaysia, at least for men.
their family but do not accept female addicts []. Moreover, it
seems that ketum dependents are not neglecting their family
and the impairment of their social functioning is still under
debate []. A recent cross-sectional survey in three northern
states of Peninsular Malaysia investigated  regular kratom
consumers []. Findings showed that regular kratom users
do not seem to experience major impairments in their
social functioning, despite being dependent on kratom for
prolonged periods []. Furthermore, ketum use does not
imply risky behaviours such as needle sharing, common in
heroin dependents []. On the other hand, evidence shows
that kratom can generate addiction problems and lead to
other social issues []. Considering how kratom use is
consistent, gures for treatment admissions for its use appear
rather low, accounting for, for example,  percent of all
drug treatment admissions in ailand in  (Figure ).
Kratom-related treatment admissions almost tripled between
 and  (Figure ) []. is could be also partially due
to a more strict antidrug policy, where individuals caught
with kratom are obliged to engage in treatment programs.
Surely, ndings show that regular kratom use is associated
with drug dependency, development of withdrawal symp-
toms, and craving []. Many regular users declare their
diculty to abstain from kratom use and experiencing
sharp unpleasant symptoms during abstinence periods [].
Physical withdrawal symptoms include anorexia, weight loss,
decreased sexual drive, insomnia, muscle spasms and pain,
aching in the muscles and bones, jerky movement of the
limbs, watery eyes/nose, hot ushes, fever, decreased appetite,
and diarrhoea [, ]. Psychological withdrawal symptoms
commonly reported are nervousness, restlessness, tension,
anger, hostility, aggression, and sadness [, ]. Long-term
addicts are described to become thin and have skin pigmen-
tation on their cheeks, due to the capacity of mitragynine
to increase the production of melanocytes-stimulating sub-
stance [, ]. Regular ketum use is also reported to cause
2007 2008 2009 2010 2011
Kratom-related treatment admissions in ailand
F : Kratom-related treatment admissions in ailand almost
tripled between  and . Source: United Nations Oce on
Drugs and Crime, Patterns and Trends of Amphetamine-Type
Stimulants and Other Drugs: Asia and the Pacic— (Bangkok,
psychotic symptoms such as mental confusion, delusion, and
hallucination [].
Regarding polydrug abuse, in Asia, patterns of com-
plex cointaking involving kratom are also reported. Beyond
classic” substances and many NPS as synthetic phenylethy-
lamines and cathinones, peculiarly there have been cases
where codeine is added into kratom drinks to obtain a
better “high” or euphoria. In southern ailand, in recent
years, homemade ice-cold cocktails, called “ ×,” have
become popular for their alleged alcohol-mimicking eect
among young Muslim people []. e cocktails are made
from kratom leaves, a caeine-containing so drink, and
codeine- or diphenhydramine-containing cough syrup as the
three basic ingredients to which ice cubes, an anxiolytic, an
antidepressant, or an analgesic drug is added [, ].
So far, there have not been any mortality or toxicity
incidents directly related to ketum use reported in Asian
countries. One possibility is that ketum users in Asia nor-
Traditionally, ketum in Asia has been used for its stimulant
eects and the dose consumed might be lower than the
one consumed for recreational purposes []. But it is also
possible that local health care providers in Asia, perceiving
ketum as a safe traditional herbal drink, might not attribute
some of the medical problems reported by users to ketum use;
this factor may indeed contribute to the underreporting of
adverse eects among ketum users in Southeast Asia.
3.3. Kratom Use in Western Countries
3.3.1. Diusion, Modalities, and Reasons of Consumption. In
recent years kratom has become popular in the EU, US,
BioMed Research International
and other countries (e.g., Japan) as a recreational novel
compound[,,].AvarietyofMitragyna speciosa related
products are easily accessible from local smart shops and
increasingly available forsale on the Internet, in particular on
web based “legal highs” pharmacies, but their exact content is
not always veried [, ]. Many dierent formulations are
available, including raw leaves, capsules, tablets, powder, and
concentrated extracts []. Prices vary between countries,
depending on the type and amount of the purchased product,
X” extracts,  to  euros per  gram for dried kratom [],
or sometimes even for lower prices (from less than  euro per
gram for “kratom power”) [, –].
Mitragyna speciosa and/or mitragynine and/or -hydrox-
ymitragynine are currently controlled only in a small number
of EU Member States, such as Denmark, Latvia, Lithuania,
Poland, Romania, and Sweden []. Kratom is also largely
uncontrolled in the US at a federal level while at the state
level there are some exceptions such as Indiana, Iowa,
Louisiana, and Massachusetts. is means all parts of the
plant and its extracts are legal to cultivate, buy, possess, and
distribute without a license or prescription, and, when sold
as a supplement, sales must conform to US supplement laws
[]. Recently, in February , the Food and Drug Admin-
istration (FDA) issued “Import Alert -” that seems to
provide customs and border agents broad authority to seize
kratom products from a number of suppliers outside the US
As kratom is oen not monitored in national drug abuse
surveys, there is still little information on prevalence of its
use. An initial warning about this phenomenon has been
launched by the Drug Enforcement Administration (DEA)
as early as  []. Internet surveys conducted by the
EMCDDA in  indicated that kratom was one of the most
widely oered “legal highs” in % of the investigated 
online shops across the EU []. A more extensive EMCDDA
Internet survey in July  showed that kratom was the
most widely oered product with  out of  (or %) of
online retailers shipping it to the EU. A further online study
identied  online shops selling NPS that would dispatch
products to at least one EU Member State (United Kingdom
appeared to be the most common) []. Kratom and Salvia
divinorum were the most frequently oered NPS, available
in  and  online shops, respectively []. In  the term
“kratom” was found in more than two million results. Of the
rst  websites listed in the search results,  were primarily
focused on the sale of kratom, while  were focused on
disseminating information about kratom through the use of
discussion boards [].
3.3.2. Subjective Experience: Online Reports. Since , an
exponential growing number of kratom’s subjective experi-
ences have been posted online by users (Box ) [, –].
advantage over chewing or making a tea: the amount of leaves
that constitutes a typical dose is too much to be smoked
easily [, ]. A paste-like extract can be prepared by lengthy
boiling of fresh or dried leaves and the syrup produced can
pills and smoked in pipes (“madatin”) []. Small pellets of
dissolved in hot water and consumed alone or mixed with
other ordinary herbal teas to make it more palatable (the so-
beverages or to ingest it with food, mixing it with yoghurt or
preparing cookies, in order to contrast the bitterness of the
compound [, ]. Regarding desired/recreational eects of
kratom, users report that at low doses it is rather stimulant,
mind is “more alert,” physical energy and sometimes sexual
arousal are increased, and ability to do physical work may
be improved and they also described “entactogenic” eects,
like empathy and euphoria (Box ) [, , ]. Some people
nd this level edgy rather than pleasant [, ]. At higher
doses, experiences describe it as more sedative and analgesic;
users prefer to be less sensitive to physical or emotional
pain, to feel and look calm, and to have a general feeling of
comfortable pleasure [, ]. Others report an increase of
empathy feelings (Box ) [].
3.3.3. Side-Eects. A variety of less explored side-eects
experienced by users also emerged from our work (Table ).
ese frequently include nausea, constipation, sleep prob-
lems, temporary erectile dysfunction, itching, and sweating
and also hyperpigmentation and tremor and anorexia and
weight loss in long term [, –]. Some users describe
hair loss, probably related to a regular (daily) use of kratom
[]. Withdrawal symptoms are also common, including
muscle aches, irritability, mood disturbances, runny nose,
diarrhoea, and muscle jerking (Table ) []. Users describe
tolerance (requiring the consumption of higher doses to
achieve the same eects) and also a “cross-tolerance” to
both kratom and opiates aer repeated intake [, –].
Moreover, kratom is increasingly purchased from Internet
sources for self-medication [, ], especially by individuals
with chronic pain to self-manage opioid withdrawal [, ]
or heroin, methadone, or suboxone withdrawal symptoms
[], or for its anxiolytic and antidepressant eects [].
For this reason, it is oen advertised online as a cheaper
alternative to traditional opioid replacement therapies with
no need of medical prescription []. is could pose a
serious problem for doctors prescribing pain medication or
opioid substitution therapy to someone who is a regular
kratom user. Adverse eects and intoxications cases across
various countries have also been reported, including liver
toxicity, seizure, and coma [, –], reports of patients
suering from intrahepatic cholestasis aer two weeks of
kratom use [], Adult Respiratory Distress Syndrome [],
and hypothyroidism [] (Table ). Evidence also suggests
that kratom might be a deadly substance when mixed with
other compounds (Table ). Fatalities resulting from the use
of a kratom-based product known as “Krypton” have also
been reported [] with  documented cases in Sweden
[]. Subsequent forensic studies revealed that Krypton
contained high amounts of the exogenous pharmaceutical
agent O-desmethyltramadol, an opioid analgesic and the
main active metabolite of tramadol, and it had been added
to the plant material. e presence of this contaminant
in some online products is well documented [, , ].
BioMed Research International
“About twenty minutes aer ingesting the Kratom, I began to feel a nice, pleasant euphoria
identical to that of an opiate...I did notice the simultaneous stimulant/depressant eect like
I notice in hydrocodone or oxycodone”
“I start to feel this intense warmth come over my entire body, it feels like a combination of
my rst MDMA high with a nice OxyContin like twist, along with the social aspect of
“I felt my insides become so and pliable like the onset of most trippy drugs”
“I felt relaxed, sedated, and free of my normal back and thumb pain in my right hand which
I thought would never be possible. I also felt a nice fuzzy feeling all over which I get from
smoking pot sometimes”
“I began oating in and out of waking dreams, the ‘nod’, whatever you want to call it, where
you’re not really asleep but you still see dreamlets and dream fragments oating before your eyes.
is goes on for quite some time”.
“I lost track of time at this point, as I was completely lost in the music and my own thoughts. I
wasn’t really feeling euphoria or a ‘high,’ like when using marijuana. I did feel very ‘stoned’ though,
and I guess I would refer to my state as being high because of my total relaxation and
“When I’m at the peak, I feel a very pleasant body buzz, kind of like being wrapped around a warm,
so blanket all day long. On the comedown, I feel relaxed but scatterbrained and my
concentration takes a hit, and I can easily enter ‘waking dreams’ where I’m not sleeping but
dreaming while being unaware of either state of consciousness, which oen causes me to jolt
awake and open my eyes”
B : Qualitative analysis of kratom users’ experiences.
Even though mitragynine was also detected in the products,
it was not determined how the two substances may have
interacted to cause death. Other “deadly cases” are available:
an article described a fatal reaction that appeared to be asso-
ciated with mixing with propylhexedrine (an 𝛼-agonist and
amphetamine-like stimulant, used as decongestant inhalers);
another case indicated that a mix of kratom, over-the-counter
cold medications, and benzodiazepines was responsible for
the death of a -year-old boy; a postmortem detection of
kratom together with venlafaxine, diphenhydramine, and
mirtazapine was screened in a -year man found unrespon-
sive in bed; a middle aged man in therapy with zopiclone,
citalopram, and lamotrigine was found dead at home and
postmortem analysis of peripheral blood revealed high con-
centrations of mitragynine and -hydroxymitragynine and
therapeutic values of intake of the other compounds [, ,
It must also be noted that kratom is commonly taken
in combination with a variety of other recreational “classic
drugs” (e.g., alcohol, cannabis, benzodiazepines, methadone,
cocaine, amphetamine, and hallucinogenic mushrooms) and
NPS (e.g., kava, mephedrone, and other synthetic cathinones,
tryptamines, and phenylethylamines such as C-E, AL-LAD,
and -HO-MiPT) [].
4. Discussion and Conclusions
Indeed, the use of substances to enhance human abilities
is a constant and cross-cultural feature in the evolution of
cultures for therapeutic purposes, religious ceremonies, and
improvement or modication of the physical and mental
abilities. Although much has changed over time, the drive
for human enhancement has not diminished and drugs
availability on the Internet, oen supported by misleading
marketing strategies, has made their use even more likely and
risky []. In this context,the tropical tree Mitragyna speciosa
Korth. (kratom) has now planted its “roots” of use worldwide.
Although the phenomenon has only been marginally studied,
an exponential number of kratom’s subjective experiences
have been posted online on drug fora by users in the EU
and US and elsewhere. Kratom, still easily available in native
countries, is now just “a click” away and potentially available
BioMed Research International
T : Report of adverse/toxicological eects of kratom.
Short time use eects
Nausea, constipation, sleep problems,
temporary erectile dysfunction,
itching, or sweating
Long time use eects Anorexia, dry mouth, problems in
diuresis, darker skin, and hair loss
Hostility, aggression, aching of muscles
and bones, jerky movements of the
limbs, anorexia and weight loss, and
Infrequent eects
Seizures (individuals using high doses
of kratom, either alone or combined
with other drugs), intrahepatic
cholestasis, psychotic symptoms, Adult
Respiratory Distress Syndrome, and
Kratom mixed with other substances:
over-the-counter cold medications and
venlafaxine, diphenhydramine, and
zopiclone, citalopram, and lamotrigine
to wide range of new users, including vulnerable individuals.
As it emerged from our previous studies [, –], the web
serves also as a repository of information for selected groups,
who can share experiences and suggest new products or
novel modalities of intake via online fora, chat-rooms, blogs,
videos, and others.
Anthropologically, drug addiction history is the complex
history of human vicissitude and desire, as human being is a
desiring being, trying in every way to assuage suerings, to
enhance feelings of pleasure, and to satisfy inexhaustible and
incessant desires []. Even today, the line between socially
acceptable and unlawful use of a variety of psychoactive
products seems to be culture-bound. Kratom is a plant with
a well-established traditional use in South Asia to enhance
work abilities as well as support traditional medicine and
culture, even if ocially banned. At the same time, its rapid
diusion in Western societies, where it is oen considered a
“natural” and thus safer option than illicit drugs or an alter-
native to opioid treatment, is not devoid of risks. According
to preclinical data and case reports published in scientic
literature as well as anecdotal experiences posted online,
kratom is not a safe drug. Its consumption is associated
per se with drug dependency, development of withdrawal
symptoms, craving, serious adverse eects, and life-threating
eects, especially in a multidrug-intoxicating scenario [,
, , ]. Furthermore, the idea that legality can equate
with the safety of a product might still remain a common
insidious misbelief amongst drug users []. On the other
hand, Suwanlert has pointed out in  that “it is hoped
that drug education will be a more eective step towards
kratom use control” [], foreseeing the failure of the legislative
measures in South Asian countries.
Kratom pharmacology itself is complex and requires
future research: this compound in fact acts on opioid as well
as on dopaminergic, serotonergic, GABAergic, and adren-
ergic systems [, ]. erefore, subjective eects are very
peculiar ranging from psychostimulant to sedative-narcotic.
Pharmacological mechanisms responsible for several of its
alkaloids activity deserve yet to be clearly established in future
studies. Altogether, available data on kratom suggest caution:
this unregulated plant could exhibit a serious harmful poten-
tial, far beyond any “therapeutic” desired eect; in parallel, its
anxiolytic, antidepressant, and analgesic properties need to be
better explored by scientic research works, like, for example,
in large blind randomized controlled clinical trials [].
Potential users who tend to self-medicate and health
professionals working with them should be clearly aware of
the risks associated with kratom consumption []. As it
emerged from this and other previous studies [], kratom
is advertised and sold online as “cheaper alternative” to
traditional opioid replacement therapies, as a painkiller for
chronic pain, or as an anxiolytic remedy in psychiatric
population, with no need of medical prescription or supervi-
sion. is encourages a tendency to self-medicate and could
become a serious problem for unaware doctors prescribing
medication to a patient who is a regular kratom user or in
case of acute intoxication related to the substance. Another
issue of concern is the action of other isolated compounds
(e.g., speciociliatine, speciogynine, and paynantheine) whose
eects were not inhibited by naloxone in animal studies [,
], meaning a potentially very dicult management in case
of overdose. erefore, in this scenario, the risk of adverse
reactions or possible misdiagnosis might be very high. It
might also be worth adding that kratom use is not detected
by conventional drug screening tests as advanced tests, like
liquid chromatography-tandem or ion-mass spectrometry,
focusing and asking direct questions on the nature and
patterns of drug intake, including medical products diversion
and consumption of NPS, during clinical assessments [].
Given that nowadays polydrug use represents the norm rather
than the exception, especially in emergency settings [], the
simultaneous use of drugs should also be promptly iden-
tied, investigated, and well discriminated. Future studies
should explicitly examine the eects of the combination in
complex patterns of polydrug intake, including kratom, to
fully understand the synergistic eects and associated clinical
and toxicological implications. Attention should also be paid
to the motivations behind such behaviours, social norms,
stigma, availability, and other lifestyle factors.
Surely, a possible limitation of our analysis could be
given by the fact that publicly available websites, fora, and
similar sources were also considered and included together
with a systematic literature review. One could wonder about
the limitations of carrying out a risk assessment of a drug
while taking into account also the online comments. It may
be inappropriate to trust information obtained from the
Internet without independent verication and we did not
have any possibility here to ascertain if the substance the
online alleged drug users were taking was indeed kratom. On
the other hand, online reports about kratom seem genuine
BioMed Research International
and many users illustrate their detailed experiences as proper
experiments on themselves. us, in the lack of relevant peer-
reviewed data, the online monitoring seems to be indeed a
very useful method to obtain preliminary information about
new and emergent phenomena []. Further, as demon-
strated by the outcomes of this study, a better international
collaboration is necessary to tackle this rapidly growing drug
Conflict of Interests
e authors declare that there is no conict of interests
regarding the publication of this paper.
is publication arises from collaborative activities and
sta exchanges among collaborating institutions funded by
the European Commission. e authors would also like
to acknowledge the contribution of the Canadian Centre
on Substance Abuse (CCSA), the Public Health Agency of
Canada, and the World Health Organization (WHO) for
granting access to the Global Public Health Intelligence
Network (GPHIN) database to support the web-monitoring
[] S. Suwanlert, “A study of kratom eaters in ailand,” Bulletin on
[] K. Ahmad and Z. Aziz, “Mitragyna speciosa use in the northern
states of Malaysia:a cross-sectional study,Journal of Ethnophar-
[] “European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA)—Kratom Drug prole,” http://ww w.emcdda.euro-les/kratom.
[] C. Ruck and M. A. Homan, Mushrooms, Myth and Mithras:
e Drug Cult at Civilized Europe,CityLightsBooks,San
Francisco, Calif, USA, .
[] W.C.Prozialeck,J.K.Jivan,andS.V.Andurkar,“Pharmacol-
ogy of Kratom: an emerging botanical agent with stimulant,
analgesic and opioid-like eects,” Journal of the American
Osteopathic Association,vol.,no.,pp.,.
[] United Nations Oce on Drugs and Crime (UNODC), Wo r l d
Drug Report 2014, United Nations Publication, .
[] P. Dargan and D. Wood, Novel Psychoactive Substances. Clas-
sication, Pharmacology and Tossicology, Academic Press, New
Yo r k , N Y, U S A ,     .
mitragynine and O-desmethyltramadol in Kratom and legal
high products sold online,Drug Testing and Analysis,vol.,no.
, pp. –, .
[] O. Corazza, S. Assi, P. Simonato et al., “Promoting innovation
and excellence to face the rapid diusion of novel psychoactive
substances in the EU: the outcomes of the reDNet project,”
Human Psychopharmacology,vol.,no.,pp.,.
[] J. M. Stogner, “Predictions instead of panics: the framework
and utility of systematic forecasting of novel psychoactive drug
trends,e American Journal of Drug and Alcohol Abuse,vol.
, no. , pp. –, .
[] N. Harun, Z. Hassan, V. Navaratnam, S. M. Mansor, and M.
Shoaib, “Discriminative stimulus properties of mitragynine
(kratom) in rats,Psychopharmacology,vol.,no.,pp.
, .
[] H. Takayama, “Chemistry and pharmacology of analgesic
indole alkaloids from the rubiaceous plant, Mitragyna speciosa,”
Chemical and Pharmaceutical Bulletin,vol.,no.,pp.
, .
[] S. ongpradichote, K. Matsumoto, M. Tohda et al., “Identi-
cation of opioid receptor subtypes in antinociceptive actions of
supraspinally-administered mitragynine in mice,Life Sciences,
vol. , no. , pp. –, .
[] D. Ponglux, S. Wongseripipatana, H. Takayama et al., “A
new indole alkaloid,  alpha-hydroxy-H-mitragynine, from
Mitragyna speciosa in ailand,Planta Medica,vol.,no.,
[] S. Horie, F. Koyama, H. Takayama et al., “Indole alkaloids
of a ai medicinal herb, Mitragyna speciosa, that has opioid
agonistic eect in guinea-pig ileum,Planta Medica,vol.,no.
[] Z. Utar, M. I. A. Majid, M. I. Adenan, M. F. A. Jamil, and T. M.
Lan, “Mitragynine inhibits the COX- mRNA expression and
prostaglandin E2production induced by lipopolysaccharide in
RAW. macrophage cells,” Journal of Ethnopharmacology,
vol. , no. , pp. –, .
oder, H. Neurath et al., “Behavioral and
neurochemical characterization of kratom (Mitragyna speciosa)
[] K. Matsumoto, M. Mizowaki, T. Suchitra et al., “Central
antinociceptive eects of mitragynine in mice: contribution of
descending noradrenergic and serotonergic systems,European
Journal of Pharmacology,vol.,no.,pp.,.
[] I. Ujv´
ary, “Psychoactive natural products: overview of recent
developments,Annali dell’Istituto Superiore di Sanita,vol.,
no. , pp. –, .
[] A. Sabetghadam, S. Ramanathan, S. Sasidharan, and S. M.
Mansor, “Subchronic exposure to mitragynine, the principal
alkaloid of Mitragyna speciosa,inrats,Journal of Ethnophar-
[] , Kratom,
.uk/   archive.html.
[] B. G. Backstrom, G. Classon, P. L¨
owenhielm, and G. elander,
“Krypton—new, deadly internet drug. Since October  have
nine young persons died in Sweden,Lakartidningen,vol.,
no. , pp. –, .
[] J. M. Holler, S. P. Vorce, P. C. McDonough-Bender, J. Magluilo
Jr., C. J. Solomon, and B. Levine, “A drug toxicity death involving
propylhexedrine and mitragynine,Journal of Analytical Toxi-
[] S. Ramanathan, S. Parthasarathy, V. Murugaiyah, E. Magosso,
S. Tan, and S. Mansor, “Understanding the physicochemical
properties of mitragynine, a principal alkaloid of Mitragyna
speciosa, for preclinical evaluation,” Molecules,vol.,no.,pp.
–, .
[] V. K. Manda, B. Avula, Z. Ali, I. A. Khan, L. A. Walker, and
S. I. Khan, “Evaluation of in vitro absorption, distribution,
metabolism, and excretion (ADME) properties of mitragynine,
-hydroxymitragynine, and mitraphylline,Planta Medica,vol.
, no. , pp. –, .
[] J. Azizi, S. Ismail, and S. M. Mansor, “Mitragyna speciosa Korth
leaves extracts induced the CYP catalyzed aminopyrine-
N-demethylase (APND) and UDP-glucuronosyl transferase
 BioMed Research International
(UGT) activities in male Sprague-Dawley rat livers,Drug
Metabolism and Drug Interactions,vol.,no.,pp.,
[] N. A. Hanapi, S. Ismail, and S. M. Mansor, “Inhibitory eect
of mitragynine on human cytochrome P enzyme activities,
Pharmacognosy Research,vol.,no.,pp.,.
[] Z.Hassan,M.Muzaimi,V.Navaratnametal.,“FromKratomto
mitragynine and its derivatives: physiological and behavioural
eects related to use, abuse, and addiction, Neuroscience &
Biobehavioral Reviews, vol. , no. , pp. –, .
[] A. I. Hazim, S. Ramanathan, S. Parthasarathy, M. Muzaimi,
and S. M. Mansor, “Anxiolytic-like eects of mitragynine in
the open-eld and elevated plus-maze tests in rats,Journal of
Physiological Sciences,vol.,no.,pp.,.
[] B.-S. Khor, M. F. Jamil, M. I. Adenan, and A. C. Shu-Chien,
“Mitragynine attenuates withdrawal syndrome in morphine-
withdrawn zebrash,PLoS ONE,vol.,no.,ArticleID
e, .
[] N. F. Idayu, M. T. Hidayat, M. A. M. Moklas et al., “Antidepress-
ant-like eect of mitragynine isolated from Mitragyna speciosa
Korth in mice model of depression,Phytomedicine,vol.,no.
, pp. –, .
[] A. R. Shamima, S. Fakurazi, M. T. Hidayat, I. Hairuszah, M. A.
M. Moklas, and P. Arulselvan, “Antinociceptive action of iso-
lated mitragynine from mitragyna speciosa through activation
of opioid receptor system,International Journal of Molecular
[] T. B. Goh, K. R. Yian, M. N. Mordi, and S. M. Mansor,
Antioxidant value and antiproliferative ecacy of mitragynine
and a silane reduced analogue,Asian Pacic Journal of Cancer
[] N. A. Saidin, T. Randall, H. Takayama, E. Holmes, and N. J.
Gooderham, “Malaysian Kratom, a phyto-pharmaceutical of
abuse: studies on the mechanism of its cytotoxicity,Toxico l o g y ,
vol. , no. –, pp. –, .
[] M. F. A. Jamil, M. F. M. Subki, T. M. Lan, M. I. A. Majid, and M.
I. Adenan, “e eect of mitragynine on cAMP formation and
mRNA expression of mu-opioid receptors mediated by chronic
morphine treatment in SK-N-SH neuroblastoma cell,Journal
of Ethnopharmacology,vol.,no.,pp.,.
[] S. Fakurazi, S. A. Rahman, M. T. Hidayat, H. Ithnin, M. A. M.
Moklas, and P. Arulselvan, “e combination of mitragynine
and morphine prevents the development of morphine tolerance
in mice,Molecules,vol.,no.,pp.,.
[] S. Chittrakarn, N. Keawpradub, K. Sawangjaroen, S. Kanse-
nalak, and B. Janchawee, “e neuromuscular blockade pro-
duced by pure alkaloid, mitragynine and methanol extract
of kratom leaves (Mitragy na speciosa Korth.),Journal of
[] K. Matsumoto, L. T. Yamamoto, K. Watanabe et al., “Inhibitory
eect of mitragynine, an analgesic alkaloid from ai herbal
medicine, on neurogenic contraction of the vas deferens,” Life
Sciences, vol. , no. , pp. –, .
[] J. Purintrapiban, N. Keawpradub, S. Kansenalak, S. Chittrakarn,
B. Janchawee, and K. Sawangjaroen, “Study on glucose trans-
port in muscle cells by extracts from Mitragy na speciosa (Korth)
and mitragynine,Natural Product Research, vol. , no. , pp.
–, .
[] S. Tsuchiya, S. Miyashita, M. Yamamoto et al., “Eect of
mitragynine, derived from ai folk medicine, on gastric
acid secretion through opioid receptor in anesthetized rats,
European Journal of Pharmacology,vol.,no.,pp.
, .
[] S. N. Harizal, S. M. Mansor, J. Hasnan, J. K. J. arakan, and J.
Abdullah, “Acute toxicity study of the standardized methanolic
extract of Mitragyna speciosa Korth in Rodent,Journal of
[] N.H.Yuso,F.W.Suhaimi,R.K.Vadiveluetal.,“Abusepoten-
tial and adverse cognitive eects of mitragynine (kratom),
Addiction Biology,.
[] E.Apryani,M.TaukHidayat,M.A.A.Moklas,S.Fakurazi,and
N. Farah Idayu, “Eects of mitragynine from Mitrag yna speciosa
Korth leaves on working memory,Journal of Ethnopharmacol-
ogy, vol. , no. , pp. –, .
[] F. G. Kapp, H. H. Maurer, V. Auw¨
arter, M. Winkelmann, and M.
Hermanns-Clausen, “Intrahepatic cholestasis following abuse
of powdered kratom (Mitragyna speciosa),Journal of Medical
Tox i c o l o g y ,vol.,no.,pp.,.
[] J. Lu, H. Wei, J. Wu et al., “Evaluation of the cardiotoxicity of
mitragynine and its analogues using human induced pluripo-
tent stem cell-derived cardiomyocytes,PLoS ONE,vol.,no.
, Article ID e, .
[] K. S. Grewal, “Observations on the pharmacology of mitragy-
nine,Journal of Pharmacology and Experimental erapeutics,
vol. , pp. –, .
[] K. L. Jansen and C. J. Prast, “Ethnopharmacology of kratom and
the Mitragyna alkaloids,Journal of Ethnopharmacology,vol.,
no. , pp. –, .
[] I. H. Burkill and M. Hani, “Malay village medicine,e
Garden’s Bulletin Straits Settlement,vol.,pp.,.
[] HighWise Research Group, Kratom Factsheet, University of
Hertfordshire, Hateld, UK, .
[] T. Amattayakul, “e kraton leaves,Journal of the Department
of Medical Sciences, ailand,vol.,no.,pp.,.
[] B. Vicknasingam, S. Narayanan, G. T. Beng, and S. M. Mansor,
“e informal use of ketum (Mitragyna speciosa) for opioid
withdrawal in the northern states of peninsular Malaysia
and implications for drug substitution therapy,International
Journal of Drug Policy,vol.,no.,pp.,.
[] A. Ingsathit, P. Woratanarat, T. Anukarahanonta et al., “Preva-
lence of psychoactive drug use among drivers in ailand: a
roadside survey,Accident Analysis and Prevention,vol.,no.
[] H.-J. Chang, “Health care systems in transition. II. Taiwan, part
II. e current status of HIV-AIDS in Taiwan,Journal of Public
Health Medicine, vol. , no. , pp. –, .
[] D. Singh, C. P. M¨
uller, and B. K. Vicknasingam, “Kratom
(Mitragyna speciosa) dependence, withdrawal symptoms and
craving in regular users,Drug and Alcohol Dependence,vol.,
U. Patt a nas att ayawon g , “ e use o f Mitragynine speciosa
(“Krathom”), an addictive plant, in ailand,” Substance Use
and Misuse, vol. , no. , pp. –, .
[] D. Singh, C. P. M¨
uller, B. K. Vicknasingam, and S. M. Mansor,
“Social functioning of Kratom (Mitragyna speciosa)usersin
Malaysia,Journal of Psychoactive Drugs,vol.,no.,pp.
, .
[] M. Martin, S. Vanichseni, P. Suntharasamai et al., “Risk behav-
iors and risk factors for HIV infection among participants in
the Bangkok tenofovir study, an HIV pre-exposure prophylaxis
trial among people who inject drugs,PLoS ONE,vol.,no.,
Article ID e, .
BioMed Research International 
[] D. Saingam, S. Assanangkornchai, A. F. Geater, and Q. Balthip,
“Pattern and consequences of krathom (Mitragyna speciosa
Korth.) use among male villagers in southern ailand: a
qualitative study,International Journal of Drug Policy,vol.,
[] W. Tungtananuwat and S. Lawanprasert, “Fatal x; home-
made kratom juice cocktail,JournalofHealthResearch,vol.,
no. , pp. –, .
[] M. B. Forrester, “Kratom exposures reported to Texas poison
centers,Journal of Addictive Diseases,vol.,no.,pp.
, .
[] E. W. Boyer, K. M. Babu, J. E. Adkins, C. R. McCurdy, and J.
H. Halpern, “Self-treatment of opioid withdrawal using kratom
(Mitragynia speciosa korth),Addiction,vol.,no.,pp.
, .
[] J. Hillebrand, D. Olszewski, and R. Sedefov, “Legal highs on the
Internet,Substance Use and Misuse,vol.,no.,pp.,
[], Kratom X, ,
[], “How to take kratom—tips,” http://–-tips.html/.
[] Smart-shop,
[] US Food and Drug Administration, “Import Alert -”.
[] Drug Enforcement Administration (DEA), “Selected intelli-
gence brief: herbal drug update: kratom,Microgram Bulletin,
vol. , no. , p. , .
[], Kratom reports,
ces/exp.cgi?S=&C=&OldSort=RA RDD&NewSort=RDD
[], Kratom read, , http://www.drugs-.
[], Kratomguide,
[] Daath,
qbp/in depth review of onlinekratomcom/.
[] H. Kupferschmidt, “Toxic hepatitis aer Kratom (Mitrag yna
sp.) consumption,” Clinical Toxicology,no.,p.,.
“Seizure and coma following Kratom (Mitrag ynina speciosa
Korth) exposure,Journal of Medical Toxicology,vol.,no.,
[] K. M. Roche, K. Hart, B. Sangalli, J. Leerg, and M. Bayer,
“Kratom: a case of a legal high,Clinical Toxicology,vol.,no.
, p. , .
[] V. Pathak, C. Hahn, M. Cabellon, and R. Aris, “Adult respiratory
distress syndrome secondary to the use of herbal drug kratom,
in Proceedings of the American oracic Society International
Conference Abstracts, San Diego, Calif, USA, May .
[] S. V. Sheleg and G. B. Collins, “A coincidence of addiction
to ‘kratom’ and Severe primary hypothyroidism,Journal of
Addiction Medicine,vol.,no.,pp.,.
“Unintentional fatal intoxications with mitragynine and O-
desmethyltramadol from the herbal blend krypton,Journal of
Analytical Toxicology,vol.,no.,pp.,.
[] M. F. Neerman, R. E. Frost, and J. Deking, “A drug fatality
involving Kratom,” Journal of Forensic Sciences,vol.,supple-
ment , pp. S–S, .
[] I.M.McIntyre,A.Trochta,S.Stolberg,andS.C.Campman,
“Mitragynine ‘Kratom’ related fatality: a case report with post-
mortem concentrations,Journal of Analytical Toxicology,vol.
[] F. S. Bersani, O. Corazza, G. Albano et al., “C-NBOMe:
preliminary data on pharmacology, psychoactive eects, and
toxicity of a new potent and dangerous hallucinogenic drug,
BioMed Research International,vol.,ArticleID,
pages, .
[] O. Corazza, G. Valeriani, F. S. Bersani et al., “‘Spice,’ ‘kryptonite,
‘black mamba’: an overview of brand names and marketing
strategies of novel psychoactive substances on the web,Journal
of Psychoactive Drugs,vol.,no.,pp.,.
[] O. Corazza, F. S. Bersani, R. Brunoro, G. Valeriani, G. Mar-
tinotti, and F. Schifano, “e diusion of performance and
image-enhancing drugs (PIEDs) on the internet: the abuse of
the cognitive enhancer piracetam,Substance Use and Misuse,
[] O. Corazza, P. Simonato, J. Corkery, G. Trincas, and F. Schifano,
“‘Legal highs’: safe and legal ‘heavens’? A study on the diusion,
knowledge and risk awareness of novel psychoactive drugs
among students in the UK,Rivista di Psichiatria,vol.,no.
[] F. Schifano, A. Ricciardi, O. Corazza et al., “New drugs and
role of the web: psychonaut web mapping project,Rivista di
Psichiatria, vol. , no. , pp. –, .
[] R. Santacroce, O. Corazza, G. Martinotti, F. S. B ersani, G. Valer i-
ani, and M. Di Giannantonio, “Psyclones: a roller coaster of life?
Hidden synthetic cannabinoids and stimulants in apparently
harmless products,Human Psychopharmacology: Clinical and
[] G. Valeriani, O. Corazza, F. S. Bersani et al., “Olanzapine as the
ideal ‘trip terminator’? Analysis of online reports relating to
antipsychotics’ use and misuse following occurrence of novel
psychoactive substance-related psychotic symptoms,” Human
Psychopharmacology, vol. , no. , pp. –, .
[] M. Balestrieri, C. Bellantuono, D. Berardi et al., Manuale di
Psichiatria, Il Pensiero Scientico Editore, Rome, Italy, .
[] A. Helander, M. B¨
ackberg, P. Hult´
en, Y. Al-Saar, and O.
Beck, “Detection of new psychoactive substance use among
emergency room patients: results from the Swedish STRIDA
project,” Forensic Science International,vol.,pp.,.
[] E. Cinosi, O. Corazza, R. Santacroce et al., “New drugs on the
internet: the case of Camfetamine,BioMed Research Interna-
[] P. Simonato, O. Corazza, P. Santonastaso et al., “Novel psychoac-
tive substances as a novel challenge for health professionals:
results from an italian survey,Human Psychopharmacology,
vol. , no. , pp. –, .
[] G. Martinotti, M. Lupi, T. Acciavatti et al., “Novel psychoactive
substances in young adults with and without psychiatric comor-
bidities,BioMed Research International,vol.,ArticleID
,  pages, .
adolescent with an altered state of mind,” e BMJ,vol.,
article h, .
[] O. Corazza, F. Schifano, P. Simonato et al., “Phenomenon of
methoxetamine,Human Psychopharmacology,vol.,no.,pp.
–, .
... Mitragyna speciosa , commonly known as kratom, is a tree native to Southeast Asia, particularly Thailand, Malaysia, and Indonesia. 1 The tree can grow to a height of 25 m when it reaches maturity and form its characteristic ovate-acuminate leaf shape ( Fig. 1 ). The dark green leaves present with marked pinnate venation that can be green, white, or red. ...
... All vein colors can be present on the same tree depending on age and maturity of the tree and the growth stage of the leaf. 2 Kratom is in the coffee family (Rubiaceae) and shares dose-dependent stimulant properties with the coffee shrub although it does not contain methylxanthine alkaloids such as caffeine or theophylline. 1 Kratom was first scientifically described in the 19 th century by the Dutch botanist Pieter Willem Korthals who traveled through Southeast Asia from 1830 to 1837 as part of the Dutch East India Company Commission for Natural Sciences. 3 Korthals observed a vast array of new botanical species in the Malay archipelago and brought Mitragyna speciosa back from his travels, among others ( Fig. 2 ). ...
... 11 While the official prevalence of kratom use is not known due to the plant growing abundantly, a survey conducted among 26,633 Thai households reported a lifetime kratom prevalence of 2.3% among 12-65 year old respondents which was higher than for cannabis while the prevalence was highest for 13 to 16 year old students with 9.4% in a 2004 survey. 1 At least over the past decade especially youth and young adults in Thailand have used kratom as the main ingredient in a home-made concoction, commonly referred to as "4 × 100". 12 Other active ingredients that have been occasionally identified are codeine-, or diphenhydraminecontaining cough syrup that are mixed with kratom and heated with caffeine-containing soft drinks for oral ingestion. ...
Full-text available
Kratom (Mitragyna speciosa Korth.) is a tree native to Southeast Asia with dose-dependent stimulant and opioid-like effects. Dried, powdered leaf material is among the kratom products most commonly consumed in the US and Europe, but other formulations also exist including enriched extracts, resins, tinctures, and edibles. Its prevalence in the US remains debated and the use pattern includes self-treatment of mood disorders, pain, and substance use disorders. Most of the adverse effects of kratom and its alkaloid mitragynine have been reported in the literature as case reports or part of surveys necessitating confirmation by clinical trials. Toxicities associated with kratom consumption have focused on hepatic, cardiac, and CNS effects with the potential to cause fatalities primarily as part of polydrug exposures. Kratom may also present with drug-drug interactions primarily through CYP 3A4 and 2D6 inhibition, although the clinical significance remains unknown to date. The variability in composition of commercially available kratom products complicates generalization of findings and requires further investigation by employing clinical trials. Healthcare professionals should remain cautious in counseling patients on the use of kratom in a therapeutic setting.
... However, kratom remains illegal due to its classification as a narcotic crop in a number of countries, including Thailand, where possession and use of kratom are prohibited [2,3]. At the moment, kratom is used worldwide and is easily accessible through online purchasing [4]. ...
... Kratom contains over 40 alkaloids [4]. Numerous studies have focused on two alkaloids: mitragynine and 7-hydroxymitragynine [5,6,7]. ...
... In kratom users, a brief increase in blood pressure and pulse rate was observed [16]. Additionally, kratom has been used traditionally to treat diabetes [4]. Hence, kratom use affected lipid profiles, body weight, blood pressure, and pulse rate. ...
Full-text available
Background and aims There are evidence about effects of kratom (Mitragyna speciosa) use on parameters related to metabolic syndrome (MetS). The present study aimed to determine the association between kratom use and MetS. Methods This study is a cross-sectional study of 581 subjects (kratom users and non-users) aged 18 and over from the Nam Phu sub-district, Surat Thani province, Thailand. The association was determined using multivariate logistic regression. Results MetS prevalence in kratom users and non-users was 11.9% (95% CI, 8.4–16.3%) and 21.6 % (95% CI, 17.1–26.8%), respectively. The use of kratom was associated with the lower odds of MetS (adjusted OR, 0.56; 95% CI, 0.33–0.96). Kratom use were associated with smaller waist circumference, lower triglycerides, and higher high-density lipoprotein. Conclusions The current study demonstrated a potential protective effect of kratom use against MetS.
... Kratom produces an array of psychoactive compounds. So far more than 54 compounds including alkaloids, flavonoids, and terpenoids have been identified within kratom [5][6][7]. Although kratom's alkaloids are likely produced by the plant to aid in defense of environmental challenges, they have demonstrated activity upon human central nervous system targets and may be medically valuable for the improvement of human health [8][9][10]. ...
... Although kratom's alkaloids are likely produced by the plant to aid in defense of environmental challenges, they have demonstrated activity upon human central nervous system targets and may be medically valuable for the improvement of human health [8][9][10]. Of the wide array of alkaloids found in kratom leaves, mitragynine and 7-hydroxymitragynine are the best understood and considered the most psychoactive [6]. Mitragynine can constitute up to 38.7% in traditional and commercial kratom products [5,11,12]. ...
... and 7-hydroxymitragynine (0.01-0.75%) on a weight basis [11,19]. Other major and minor alkaloids found within leaves of kratom include paynantheine (0.3-12.8% of kratom dry leaf powder or extract weight), speciogynine (0.1-5.3%), mitraphylline which functions as muscle relaxants and possess anti-inflammatory properties, and speciociliatine (0.4-12.3%) and corynantheidine (0.1-1.2%), which act as opioid agonists and adrenergic receptor [6,10,20,21]. The overall effect following consumption of kratom leaves is complex due to the interplay and range of bioactive alkaloids present [22]. ...
Full-text available
Leaves harvested from kratom [Mitragyna speciosa (Korth.)] have a history of use as a traditional ethnobotanical medicine to combat fatigue and improve work productivity in Southeast Asia. In recent years, increased interest in the application and use of kratom has emerged globally, including North America, for its potential application as an alternative source of medicine for pain management and opioid withdrawal syndrome mitigation. Although the chemistry and pharmacology of major kratom alkaloids, mitragynine and 7-hydroxymitragynine, are well documented, foundational information on the impact of plant production environment on growth and kratom alkaloids synthesis is unavailable. To directly address this need, kratom plant growth, leaf chlorophyll content, and alkaloid concentration were evaluated under three lighting conditions: field full sun (FLD-Sun), greenhouse unshaded (GH-Unshaded), and greenhouse shaded (GH-Shaded). Nine kratom alkaloids were quantified using an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method. Greenhouse cultivation generally promoted kratom height and width extension by 93–114% and 53–57%, respectively, compared to FLD-Sun. Similarly, total leaf area and leaf number were increased by 118–160% and 54–80% under such conditions. Average leaf size of plants grown under GH-Shaded was 41 and 69% greater than GH-Unshaded and FLD-Sun, respectively; however, no differences were observed between GH-Unshaded and FLD-Sun treatments. At the termination of the study, total leaf chlorophyll a+b content of FLD-Sun was 17–23% less than those grown in the greenhouse. Total leaf dry mass was maximized when cultivated in the greenhouse and was 89–91% greater than in the field. Leaf content of four alkaloids to include speciociliatine, mitraphylline, corynantheidine, and isocorynantheidine were not significantly impacted by lighting conditions, whereas 7-hydroxymitragynine was below the lower limit of quantification across all treatments. However, mitragynine, paynantheine, and corynoxine concentration per leaf dry mass were increased by 40%, 35%, and 111%, respectively, when cultivated under GH-Shaded compared to FLD-Sun. Additionally, total alkaloid yield per plant was maximized and nearly tripled for several alkaloids when plants were cultivated under such conditions. Furthermore, rapid, non-destructive chlorophyll evaluation correlated well (r2 = 0.68) with extracted chlorophyll concentrations. Given these findings, production efforts where low-light conditions can be implemented are likely to maximize plant biomass and total leaf alkaloid production.
... Kratom exhibits a complex pharmacology illustrated by its traditional use both to thwart pain [7,9] and ameliorate opioid addiction [7]. The earliest literature reports of kratom refer to its seemingly contradictory use by Malay and Thai people as a sedative opium substitute [10], an aid to opium-use cessation, and as a stimulant to combat fatigue and increase productivity [11]. These divergent applications could be explained by the mixture of structurally diverse alkaloids present in kratom leaf material, which exhibit differential binding affinities to neurochemical receptors and elicit concentration dependent effects [7,12,13]. ...
... Later, Jeng-Yeou Chear et al. [17] quantified Malaysian M. speciosa samples using the method reported by Sharma et al. [26], including an additional four alkaloids [isospeciofoline, mitragynine oxindole B, speciociliatine-N(4)-oxide, and ajmalicine (10)] in the standard mixture. Recently, Kamble et al. used an optimized method with a shorter runtime to quantify 11 kratom alkaloids (2,4,7,10,11,12,13,15, corynoxine B, corynantheidine, and isospeciofoline) in rat plasma [16]. ...
... 7-hydroxymitragynine (2) isospeciofoleine (3) speciofoline (6) corynoxine A (7) corynoxeine (8) rhynchophylline (9) ajmalicine (10) paynantheine (11) mitra-gynine (12) speciogynine (13) isopay-nantheine (14) specio-ciliatine (15) Other literature has established sonication as a rapid and useful method to extract alkaloids from M. speciosa [24,34]. This method allows a higher throughput of plant samples, which will prove useful in future analyses of many kratom plants and products. ...
Many consumers are turning to kratom (Mitragyna speciosa) to self-manage pain and opioid addiction. In the United States, an array of capsules, powders, and loose-leaf kratom products are readily available. Additionally, several online sites supply live kratom plants. A prerequisite to establishing quality control and quality assurance standards for the kratom industry, or understanding how alkaloid levels effect clinical outcomes, is the identification and quantitation of major and minor alkaloid constituents within available products and preparations. To this end, an ultra-high performance liquid chromatography-high resolution mass spectrometry method was developed for the analysis of 8 indole alkaloids (7-hydroxymitragynine, ajmalicine, paynantheine, mitragynine, speciogynine, isopaynantheine, speciociliatine, and mitraciliatine) and 6 oxindole alkaloids (isomitraphylline, isospeciofoleine, speciofoline, corynoxine A, corynoxeine, and rhynchophylline) in US-grown kratom plants and commercial products. These commercial products shared a qualitatively similar alkaloid profile, with 12 – 13 detected alkaloids and high levels of the indole alkaloid mitragynine (13.9 ± 1.1 – 270 ± 24 mg/g). The levels of the other major alkaloids (paynantheine, speciociliatine, speciogynine, mitraciliatine, and isopaynantheine) and the minor alkaloids varied in concentration from product to product. The alkaloid profile of US-grown M. speciosa “Rifat” showed high levels of the indole alkaloid speciogynine (7.94 ± 0.83 – 11.55 ± 0.18 mg/g) and quantifiable levels of isomitraphylline (0.943 ± 0.033 – 1.47 ± 0.18 mg/g). Notably, the alkaloid profile of a US-grown M. speciosa seedling was comparable to the commercial products with a high level of mitragynine (15.01 ± 0.20 mg/g). This work suggests that there are several M. speciosa chemotypes.
... Although it has no FDA-approved uses, it is promoted as a safe herbal supplement to treat pain, anxiety, fatigue, and opioid addiction [2]. However, its use can lead to dependency, addiction, and abuse as well as serious side effects, including respiratory depression, seizures, arrhythmias, and death [5,6]. At least 90 overdose deaths were attributed to kratom between 2016 and 2017 [6]. ...
... For oral ingestion, low doses (1-5 g) produce stimulant effects, while higher doses (5-15 g) induce opioid-like effects with sedation [6]. Although at least 40 alkaloids have been isolated from kratom leaves, the primary psychoactive substances in kratom are mitragynine and 7hydroxymitragynine [5]. Analysis of kratom alkaloids suggests ingestion results in the stimulation of opioid, alpha-2, and serotonin receptors [8]. ...
Kratom is a herbal and natural dietary supplement from Southeast Asia that is gaining popularity in the United States. Its leaves contain multiple psychoactive chemicals that stimulate opioid, alpha-2, and serotonergic receptors. Kratom is used as a stimulant and in the treatment of anxiety, pain, and opioid withdrawal. In most states, kratom can be purchased legally and is sold at smoke shops, gas stations, and online. To date, only limited data is available on the impact of habitual kratom use on patients undergoing anesthesia. The following case report highlights multiple anesthetic challenges posed by a heavy kratom user.
... The traditional use of kratom dates back centuries for a range of conditions, including gastrointestinal disorders, fever, and acute and chronic pain, as well as a mild stimulant used by day laborers [2] Due to its increased use outside of Southeast Asia, and especially in North America and Europe, over the past decade kratom has been studied for its pharmacological effects [3]. The fresh leaves are primarily used in its native environment to be chewed or made into a tea while dried leaf material is exported to be used in various preparations for oral consumption [4]. The primary focus of research on kratom has been on its indole and oxindole alkaloids with mitragynine viewed as the most abundant alkaloid [5]. ...
Full-text available
Kratom (Mitragyna speciosa Korth.) is a tree native to Southeast Asia with stimulant and opioid-like effects which has seen increased use in Europe and North America in recent years. Its safety and pharmacological effects remain under investigation, especially in regard to developmental and generational toxicity. In the current study, we investigated commercial kratom preparations using the nematode Caenorhabditis elegans as a translational model for toxicity and pharmacological effects. The pure alkaloids mitragynine and 7-hydroxymitragynine as well as aqueous, ethanolic, and methanolic extracts of three commercial kratom products were evaluated using a battery of developmental, genotoxic, and opioid-related experiments. As determined previously, the mitragynine and 7-hydroxymitragynine content in kratom samples was higher in the alcoholic extracts than the aqueous extracts. Above the human consumption range equivalent of 15–70 µg/mL, kratom dose-dependently reduced brood size and health of parent worms and their progeny. 7-hydroxymitragynine, but not mitragynine, presented with toxic and developmental effects at very high concentrations, while the positive control, morphine, displayed toxic effects at 0.5 mM. Kratom and its alkaloids did not affect pumping rate or interpump interval in the same way as morphine, suggesting that kratom is unlikely to act primarily via the opioid-signalling pathway. Only at very high doses did kratom cause developmental and genotoxic effects in nematodes, indicating its relative safety.
... Kratom (Mitragyna speciosa), a native plant in Southeast Asia, 1 has received public, scientific, and political attention in recent years. [2][3][4] In 2021, the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) decided against recommending a critical review of kratom, electing instead to continue surveillance of this herb. ...
Full-text available
Background Kratom ( Mitragyna speciosa) consumption and associated health effects have raised debates in the United States. Although most people using this herb do not experience adverse health effects associated with kratom use, medical providers should be knowledgeable of emerging substances and concurrent, sequential, or simultaneous use of other drugs which may impact healthcare recommendations and prescribing practices. Methods The objective of this narrative review was to elucidate selected health effects associated with using kratom—either alone or with other substances. Since scientifically controlled human subjects research on kratom use is still limited, relevant case reports were also described. Results Cardiovascular, gastrointestinal, neurological, and psychiatric effects associated with kratom use were especially notable, and in-utero exposure accompanied concern regarding a neonate’s risk for developing neonatal abstinence syndrome. Our ability to identify and understand the role of this herb in kratom-associated fatalities is complicated since kratom is not routinely screened for in standard forensic toxicology. If a screening is performed, it is usually for the major alkaloid, mitragynine, as a surrogate for kratom use. In addition to lacking a standard practice of screening decedents for kratom alkaloids, the association between mortality and kratom use may be confounded by polysubstance use, adulteration of kratom products, and drug-herb interactions. Conclusions Increasing medical awareness of this herb is vital to ensuring prompt administration of best-practice medical advice or treatment for people seeking information related to kratom use or for patients experiencing an adverse health effect that may be associated with using or withdrawing from kratom. Knowledge gained from continued surveillance and study of kratom and its associated health effects may assist in guiding clinical decision-making and preventing development of adverse health effects among people using kratom.
... Kratom (Mitragyna speciosa Korth., Rubiaceae; also known as ketum) is made from the leaves of a tropical tree in the coffee family indigenous to Southeast (SE) Asia, where it has been used for centuries as medicine for various ailments, including hypertension, diarrhea, cough, and fever (Tanguay, 2011;Cinosi et al., 2015;Singh et al., 2016). Despite such traditional medicinal use, it is important to recognize that neither kratom, nor its constituents (e.g., "alkaloids"), nor metabolites have been approved as safe and effective medicines for any therapeutic use. ...
Full-text available
Kratom (Mitragyna speciosa Korth., Rubiaceae) is a plant native to Southeast Asia, where it has been used for centuries as a mild stimulant and as medicine for various ailments. More recently, as kratom has gained popularity in the West, United States federal agencies have raised concerns over its safety leading to criminalization in some states and cities. Some of these safety concerns have echoed across media and broad-based health websites and, in the absence of clinical trials to test kratom's efficacy and safety, considerable confusion has arisen among healthcare providers. There is, however, a growing literature of peer-reviewed science that can inform healthcare providers so that they are better equipped to discuss kratom use with consumers and people considering kratom use within the context of their overall health and safety, while recognizing that neither kratom nor any of its constituent substances or metabolites have been approved as safe and effective for any disease. An especially important gap in safety-related science is the use of kratom in combination with physiologically active substances and medicines. With these caveats in mind we provide a comprehensive overview of the available science on kratom that has the potential to i clarity for healthcare providers and patients. We conclude by making recommendations for best practices in working with people who use kratom.
... These products are widely sold through web-based stores (i.e. internet), herbal stores, and tobacco shops [17,27,29,30]. The appearance of this "new" psychoactive drug in the global market has now become a matter of concern in terms of marketing control. ...
Opioid use disorder (OUD) has become a significant public health issue worldwide. Methadone and buprenorphine are the most common medications used for treating OUD. These drugs have the potential to assist many patients in managing their opioid dependence and withdrawal but they are currently misused and associated with certain compliance issues, side effects, and risk of relapse. As an opioid-like herbal supplement, Mitragyna speciosa Korth or kratom has received increased attention for managing chronic pain and opioid withdrawal symptoms. Nevertheless, the use of kratom as a self-treatment medication for opioid dependence continues to be controversial due to concerns raised about its effectiveness, safety, and abuse liability. The main active alkaloid constituent of the plant, mitragynine, has been shown to act as a partial mu-opioid agonist. Given this pharmacology, studies have been focusing on this psychoactive compound to examine its potential therapeutic values as medication-assisted therapy (MAT). This review aims to provide a current preclinical overview of mitragynine as a prospective novel option for MAT and summarise the recent developments in determining if the plant’s active alkaloid could provide an alternative to opioids in the treatment of OUD.
Background: Opioid agonist therapy with buprenorphine is an effective, evidence-based treatment for opioid use disorder. However, there has been increasing use of alternative substances which can still produce opioid-like effects. One of these substances is the herbal supplement kratom. The chemical composition of kratom, specifically mitragynine and 7-hydroxymitragynine, has partial mu-opioid receptor agonist and antagonist effects at the kappa- and delta-opioid receptors. Due to its addictive potential, accessibility, and legal status, there have been increasing cases of kratom use disorder (KUD). Thus, it is important to consider effective treatment options for this nontraditional substance. Methods: Twenty-eight patients self-identified kratom as their primary substance of use. Length of kratom use ranged between 1 month and 25 years, with an average daily kratom dose of 92 g/d. Nine patients were inducted on a buprenorphine/naloxone dose between 1 and 6 mg, 18 patients between 8 and 16 mg, and 1 patient at 20 mg. Three patients were stabilized on a dose at 4 mg, 23 patients between 8 and 16 mg, 1 patient at 18 mg, and 1 patient at 20 mg. Results: There was no correlation between stabilizing dose of buprenorphine/naloxone and past daily dose of kratom. As of March 2020, 20 of the 28 patients were still receiving outpatient buprenorphine/naloxone treatment. Six patients were lost to follow-up due to missed appointments, 1 tapered down to 0.25 mg of buprenorphine/naloxone and self-discharged, and 1 moved out of town. The rest have remained in treatment from 5 to 22 months, with an average duration of 11 months. Of the 28 patients, 68%, 82%, and 82% had negative test results for mitragynine at 4, 8, and 12 weeks of treatment, respectively. Conclusions: To our knowledge, this is the largest case series exploring long-term buprenorphine/naloxone treatment for KUD. Our findings suggest buprenorphine/naloxone can be used as an effective treatment option for KUD.
Full-text available
Mitragynine is a major bioactive compound of Kratom, which is derived from the leave extracts of Mitragyna speciosa Korth or Mitragyna speciosa (M. speciosa), a medicinal plant from South East Asia used legally in many countries as stimulant with opioid-like effects for the treatment of chronic pain and opioid-withdrawal symptoms. Fatal incidents with Mitragynine have been associated with cardiac arrest. In this study, we determined the cardiotoxicity of Mitragynine and other chemical constituents isolated using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). The rapid delayed rectifier potassium current (IKr), L-type Ca2+ current (ICa,L) and action potential duration (APD) were measured by whole cell patch-clamp. The expression of KCNH2 and cytotoxicity was determined by real-time PCR and Caspase activity measurements. After significant IKr suppression by Mitragynine (10 µM) was confirmed in hERG-HEK cells, we systematically examined the effects of Mitragynine and other chemical constituents in hiPSC-CMs. Mitragynine, Paynantheine, Speciogynine and Speciociliatine, dosage-dependently (0.1∼100 µM) suppressed IKr in hiPSC-CMs by 67% ∼84% with IC50 ranged from 0.91 to 2.47 µM. Moreover, Mitragynine (10 µM) significantly prolonged APD at 50 and 90% repolarization (APD50 and APD90) (439.0±11.6 vs. 585.2±45.5 ms and 536.0±22.6 vs. 705.9±46.1 ms, respectively) and induced arrhythmia, without altering the L-type Ca2+ current. Neither the expression,and intracellular distribution of KCNH2/Kv11.1, nor the Caspase 3 activity were significantly affected by Mitragynine. Our study indicates that Mitragynine and its analogues may potentiate Torsade de Pointes through inhibition of IKr in human cardiomyocytes.
Novel Psychoactive Substances: Classification, Pharmacology and Toxicology provides readers with background on the classification, detection, supply and availability of novel psychoactive substances, otherwise known as "legal highs." This book also covers individual classes of novel psychoactive substances that have recently emerged onto the recreational drug scene and provides an overview of the pharmacology of the substance followed by a discussion of the acute and chronic harm or toxicity associated with the substance. Written by international experts in the field, this multi-authored book is a valuable reference for scientists, clinicians, academics, and regulatory and law enforcement professionals.
Taiwan currently has one of the most dynamic economies in the world and its record in public health achievement is no less impressive. Thus it is of great interest to note that Taiwan may present a unique example of how people within a rapidly developing economy can successfully fight against the AIDS epidemic. AIDS and STD control policies are coordinated at the central level by the Department of Health of the Executive Yuan (the Cabinet). The AIDS Advisory Committee appointed by the Central Government consists of academics physicians and health officials. This committee reviews national control policies and periodically provides recommendations. The National AIDS Control programme which is implemented at all levels of the Government provides the basic framework for the prevention and control of AIDS. (excerpt)
The pharmacological self-management of novel psychoactive substance (NPS)-induced psychopathological consequences represents a fast growing phenomenon. This is facilitated by the frequent sharing of NPS intake experiences online and by the ease of access to a range of psychotropic medications from both the online and street market. Olanzapine is anecdotally reported by Web users to be the most frequent self-prescribed medication to cope with NPS-induced psychoses. Hence, we aimed here at better assessing olanzapine use/misuse for this purpose. Exploratory qualitative searches of 163 discussion fora/specialized websites have been carried out in four languages (English, German, Spanish, and Italian) in the time frame November 2012-2013. Most NPS-users allegedly self administer with olanzapine to manage related psychotic crises/"bad trips". This may be typically taken only for a few days, at a dosage range of 5-50 mg/day. Only a few research studies have formally assessed the effectiveness of olanzapine and indeed of other second-generation antipsychotics to treat NPS-induced psychosis. Olanzapine was suggested here from a range of pro drug websites as being the "ideal" molecule to terminate "bad trips". Health professionals should be informed about the risks related to olanzapine misuse. Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.
The urge to gain information on a new drug marketed online as 'Psyclone' has emerged after the death of a 38-year-old man in Bolton (UK). The fatality appeared to be a consequence of smoking this psychoactive product. From October to December 2013, qualitative searches of the Web have been carried out in English and Italian, using the keywords 'Psyclone', 'Psyclone legal high', 'Psyclone incense' and 'Psyclone research chemical' on the Google search engine and on the database provided by the Global Public Health Intelligence Network. Our research highlighted the existence of two psychoactive products labelled as Psyclone but with different contents and packaging: a herbal blend containing two synthetic cannabinoids (AKB-48 and 5f-PB-22) and a research chemical containing 50% ethylphenidate, 30% caffeine and 20% lidocaine. Desired and side effects of both compounds are explored in the paper. Being sold as a legal product, Psyclone may appeal to recreational users, who remain unaware of its real content. This is a serious public health threat, which may lead to acute intoxications and fatalities. Further studies in the field, including Internet monitoring, are therefore required. Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.